147 related articles for article (PubMed ID: 24498409)
1. Autoantibody profiling for lung cancer screening longitudinal retrospective analysis of CT screening cohorts.
Trudgen K; Khattar NH; Bensadoun E; Arnold S; Stromberg AJ; Hirschowitz EA
PLoS One; 2014; 9(2):e87947. PubMed ID: 24498409
[TBL] [Abstract][Full Text] [Related]
2. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer.
Zhong L; Coe SP; Stromberg AJ; Khattar NH; Jett JR; Hirschowitz EA
J Thorac Oncol; 2006 Jul; 1(6):513-9. PubMed ID: 17409910
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.
Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC
EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159
[TBL] [Abstract][Full Text] [Related]
4. Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial.
Walter JE; Heuvelmans MA; de Jong PA; Vliegenthart R; van Ooijen PMA; Peters RB; Ten Haaf K; Yousaf-Khan U; van der Aalst CM; de Bock GH; Mali W; Groen HJM; de Koning HJ; Oudkerk M
Lancet Oncol; 2016 Jul; 17(7):907-916. PubMed ID: 27283862
[TBL] [Abstract][Full Text] [Related]
5. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
7. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
8. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
9. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies against tumor-associated antigens in the early detection of lung cancer.
Dai L; Tsay JC; Li J; Yie TA; Munger JS; Pass H; Rom WN; Zhang Y; Tan EM; Zhang JY
Lung Cancer; 2016 Sep; 99():172-9. PubMed ID: 27565936
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Prediction Models for Identifying Malignancy in Pulmonary Nodules Detected via Low-Dose Computed Tomography.
González Maldonado S; Delorme S; Hüsing A; Motsch E; Kauczor HU; Heussel CP; Kaaks R
JAMA Netw Open; 2020 Feb; 3(2):e1921221. PubMed ID: 32058555
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.
Hazelton WD; Goodman G; Rom WN; Tockman M; Thornquist M; Moolgavkar S; Weissfeld JL; Feng Z
Math Biosci; 2012 Nov; 240(1):20-34. PubMed ID: 22705252
[TBL] [Abstract][Full Text] [Related]
13. Protocol and Rationale for the International Lung Screening Trial.
Lim KP; Marshall H; Tammemägi M; Brims F; McWilliams A; Stone E; Manser R; Canfell K; Weber M; Connelly L; Bowman RV; Yang IA; Fogarty P; Mayo J; Yee J; Myers R; Atkar-Khattra S; Lam DCL; Rosell A; Berg CD; Fong KM; Lam S;
Ann Am Thorac Soc; 2020 Apr; 17(4):503-512. PubMed ID: 32011914
[No Abstract] [Full Text] [Related]
14. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
[TBL] [Abstract][Full Text] [Related]
15. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
[TBL] [Abstract][Full Text] [Related]
16. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
17. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience.
Menezes RJ; Roberts HC; Paul NS; McGregor M; Chung TB; Patsios D; Weisbrod G; Herman S; Pereira A; McGregor A; Dong Z; Sitartchouk I; Boerner S; Tsao MS; Keshavjee S; Shepherd FA
Lung Cancer; 2010 Feb; 67(2):177-83. PubMed ID: 19427055
[TBL] [Abstract][Full Text] [Related]
18. Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of esophageal cancer.
Qin JJ; Wang XR; Wang P; Ren PF; Shi JX; Zhang HF; Xia JF; Wang KJ; Song CH; Dai LP; Zhang JY
Asian Pac J Cancer Prev; 2014; 15(6):2635-40. PubMed ID: 24761876
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer.
Khattar NH; Coe-Atkinson SP; Stromberg AJ; Jett JR; Hirschowitz EA
Cancer Biol Ther; 2010 Aug; 10(3):267-72. PubMed ID: 20543565
[TBL] [Abstract][Full Text] [Related]
20. Multimodal lung cancer screening using the ITALUNG biomarker panel and low dose computed tomography. Results of the ITALUNG biomarker study.
Carozzi FM; Bisanzi S; Carrozzi L; Falaschi F; Lopes Pegna A; Mascalchi M; Picozzi G; Peluso M; Sani C; Greco L; Ocello C; Paci E;
Int J Cancer; 2017 Jul; 141(1):94-101. PubMed ID: 28387927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
